Haisco Pharmaceutical Group Co., Ltd.
002653
Kedudukan dalam Saham
#2011
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Harga Saham
$9.03
Modal Pasaran
$10.30B
Perubahan (1 hari)
4.55%
Perubahan (1 tahun)
24.15%
Negara
CN
Perdagangan Haisco Pharmaceutical Group Co., Ltd. (002653)
Kategori
Healthcare
Hasil untuk Haisco Pharmaceutical Group Co., Ltd. (002653)
Hasil pada Jun 2026 TTM: $794.50M
Menurut laporan kewangan terkini daripada Haisco Pharmaceutical Group Co., Ltd., hasil semasa syarikat (TTM) ialah $794.50M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $473.97M peningkatan berbanding hasil pada tahun 2022 iaitu $437.13M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Haisco Pharmaceutical Group Co., Ltd. dari 2008 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $794.50M | 55.83% |
| 2024 | $509.84M | 7.57% |
| 2023 | $473.97M | 8.43% |
| 2022 | $437.13M | 0.18% |
| 2021 | $436.34M | -14.39% |
| 2020 | $509.68M | -9.86% |
| 2019 | $565.44M | 13.51% |
| 2018 | $498.16M | 74.62% |
| 2017 | $285.29M | 37.97% |
| 2016 | $206.77M | 10.75% |
| 2015 | $186.71M | -4.47% |
| 2014 | $195.45M | 19.47% |
| 2013 | $163.60M | 27.19% |
| 2012 | $128.62M | 34.15% |
| 2011 | $95.88M | 8.81% |
| 2010 | $88.11M | 24.14% |
| 2009 | $70.98M | 36.50% |
| 2008 | $52.00M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 1,488.97% |
US
|
|
| $2.23B | 180.43% |
US
|
|
| $15.74B | 1,881.68% |
AU
|
|
| $6.02B | 657.88% |
NL
|
|
| - | - |
CH
|
